Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type2 diabetes mellitus: A cluster randomized controlled trial

Diabetic Medicine

Volumn 29, Issue 4, 2012, Pages 531-540

  Webb, D R ^a   Khunti, K ^b   Gray, L J ^b   Srinivasan, B T ^a   Farooqi, A ^b   Wareham, N ^c   Griffin, S C ^c   Davies, M J ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ADULT; ALGORITHM; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN TREATMENT; INTENSIVE CARE; INTENSIVE MULTIFACTORIAL INTERVENTION; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SHORT FORM 12; SYSTOLIC BLOOD PRESSURE;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; CLUSTER ANALYSIS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MASS SCREENING; QUALITY OF LIFE; RISK FACTORS;

EID: 84858184987     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03441.x     Document Type: Article

References (28)

1. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009; 32: S13-S61.
2. Paddison CAM, Eborall HC, Sutton S, French DP, Vasconcelos J, Toby Prevost A et al. Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. Br Med J 2010; 340: 84.
3. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E et al. Screening for type2 diabetes: literature review and economic modelling. Health Technol Assess 2007; 11: 1-146.
4. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT et al. Different strategies for screening and prevention of type2 diabetes in adults: cost effectiveness analysis. Br Med J 2008; 336: 1180-1184.
5. Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008; 51: 1127-1134.
6. Spijkerman AM, Adriaanse MC, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM et al. Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care 2002; 25: 1784-1789.
7. Yusuf PS, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
8. Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. J Am Med Assoc 2007; 297: 286-294.
9. Gaede P, Lund-Andersen H, Parving H, Pedersen O. Effect of a multifactorial intervention on mortality in type2 diabetes. N Engl J Med 2008; 358: 580-591.
10. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type2 diabetes. N Engl J Med 2003; 348: 383-393.
11. Bellary S, O'Hare JP, Raymond NT, Gumber A, Mughal S, Szczepura A et al. Enhanced diabetes care to patients of south Asian ethnic origin (the UK Asian Diabetes Study): a cluster randomised controlled trial. Lancet 2008; 371: 1769-1776.
12. Webb DR, Khunti K, Srinivasan B, Gray LJ, Taub N, Campbell S et al. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multifactorial cardiovascular risk intervention in people with type2 diabetes mellitus detected by screening. Trials 2010; 11: 16.
13. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BHR, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type2 diabetes detected by screening. Int J Obes 2000; 24: S6-S11.
14. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in typeII diabetes (UKPDS56). Clin Sci 2001; 101: 671-679.
15. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
16. NICE. Management of Type2 Diabetes. Management of Blood Pressure, Blood Lipids and Blood Glucose levels. Guideline CG66. London: National Institute for Clinical Excellence, 2010.
17. Ware JE, Kosinski M, Keller SD. SF-12-How to Score the SF-12 Physical and Mental Health Summary Scales. Boston: Health Insitute, 1995.
18. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychology Measurement in Diabetes Research and Practice, 1st edn. Chur, Switzerland: Harwood Academic Publishers, 1994: 111-132.
19. Samanta A, Burden AC, Fent B. Comparative prevalence of non-insulin-dependent diabetes mellitus in Asian and white Caucasian adults. Diabetes Res Clin Pract 1987; 4: 1-6.
20. Campbell MK, Elbourne DR, Altman DG. CONSORT statement: extension to cluster randomised trials. Br Med J 2004; 328: 702-708.
21. Webb DR, Gray LJ, Khunti K, Srinivasan B, Taub NT, Campbell S et al. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia 2011; 54: 2237-2246.
22. Index of Multiple Deprivation (IMD). Available at Last accessed 21 September 2011.
23. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT et al. Effects of intensive glucose lowering in type2 diabetes. N Engl J Med 2008; 358: 2545-2559.
24. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with Type2 diabetes. N Engl J Med 2008; 358: 2560-2572.
25. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J et al. Age at initiation and frequency of screening to detect type2 diabetes: a cost-effectiveness analysis. Lancet 2010; 375: 1365-1374.
26. Janssen PG, Gorter KJ, Stolk RP, Rutten GEHM. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type2 diabetes: 1-year data from the ADDITION-Netherlands study. Br J Gen Pract 2009; 59: 43-48.
27. Lawrence JM, Bennett P, Young A, Robinson AM. Screening for diabetes in general practice: cross-sectional population study. Br Med J 2001; 323: 548-551.
28. Sargent LA, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT et al. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Br Med J 2010; 27: 995-1003.